Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-03-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
董事会关于独立董事独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence self-assessment of independent directors. It discusses compliance with regulatory rules about independent directors and their independence evaluation. It does not contain financial data, earnings, or management discussion of financial results. It is a governance-related report focusing on board and director matters, specifically about independent directors' independence. Therefore, it fits best under Board/Management Information (MANG), which covers announcements about board or senior management matters.
2024-03-29 Chinese
独立董事提名人声明与承诺（王艳梅）
Board/Management Information Classification · 95% confidence The document is a nomination statement and commitment declaration for an independent director candidate at Shenzhen Microchip Biotechnology Co., Ltd. It details the qualifications, independence criteria, and compliance with relevant laws and regulations for the nominee. There is no financial data, no report or results, no meeting materials, no voting results, no legal proceedings, no capital changes, and no earnings information. The document is a formal announcement related to board/management information, specifically about the nomination of a board member. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2024-03-29 Chinese
关于使用部分超募资金永久性补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the use of part of the over-raised funds to permanently supplement working capital. It details board and supervisory meetings, approvals, regulatory compliance, and the need for shareholder approval at the 2023 annual general meeting. The document does not contain financial statements or detailed financial data but is a formal announcement about the use of funds and related approvals. It is relatively short (2997 characters) and serves as a regulatory announcement about capital use and upcoming shareholder meeting approval. Therefore, it fits best under Capital/Financing Update (CAP) as it concerns the use of raised capital and financing activities.
2024-03-29 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "2023 年年度报告" which translates to "2023 Annual Report." It contains detailed sections including a letter to shareholders, company overview, financial data, management discussion and analysis, governance, and audit information. The document length is substantial (15,000 characters), and it includes comprehensive financial and operational data for the fiscal year 2023. It also references an audit report by KPMG with an unqualified opinion, which is typical for an annual report. The presence of detailed financial statements, management discussion, and analysis confirms this is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-03-29 Chinese
关于修改公司章程的公告
Governance Information Classification · 95% confidence The document is an announcement regarding amendments to the company's articles of association (company bylaws), including changes to registered capital, share capital, board size, and supervisory board size. It references legal compliance and states that the amendments will be submitted to the 2023 annual shareholders' meeting for approval. The document is a formal announcement of corporate governance changes and does not contain financial statements or detailed financial data. It is not a full annual report, interim report, or any financial report. It is also not a direct management report or remuneration report. The content fits best under Governance Information (CGR) as it details changes to the company's internal rules and governance structure.
2024-03-29 Chinese
2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed financial data for the year 2023, including total assets, net profit, revenue, and quarterly breakdowns. It also includes management discussion and analysis sections, company business overview, industry analysis, shareholder information, and risk disclosures. The document is over 12,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of audited financial figures and comprehensive business and financial information aligns with the characteristics of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification letter, so it should not be classified as RPA or RNS. Therefore, the document is best classified as an Annual Report (10-K). FY 2023
2024-03-29 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.